PegBio Co., Ltd. (HKG:2565)

Market Cap	18.53B
Revenue (ttm)	n/a
Net Income (ttm)	-242.62M
Shares Out	385.96M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400,500
Average Volume	737,387
Open	44.40
Previous Close	43.90
Day's Range	43.24 - 47.18
52-Week Range	8.68 - 46.32
Beta	n/a
RSI	86.32
Earnings Date	Aug 26, 2025

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. The company’s products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the...

• Industry: Paper & Paper Products
• Sector: Materials
• Founded: 2008
• Employees: 53
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2565

Financial Performance

Financial numbers in CNY